Acceleron Pharma Inc. (XLRN) Trading at $48.60 after Inrease

June 29, 2018 - By Eric Painter

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

Big Money Sentiment increased to 1.27 in 2018 Q1. It has change of 0.18, from 2017Q4’s 1.09. The ratio increased due to Acceleron Pharma Inc. positioning: 13 sold and 39 reduced. 24 funds took holdings and 42 increased holdings. Investors holded 38.14 million in 2017Q4 but now own 38.30 million shares or 0.44% more.
C Worldwide Grp Hldgs A S has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Ameritas Inv Partners Inc invested 0.01% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Bancorporation Of Mellon Corp, New York-based fund reported 166,076 shs. Meeder Asset Mngmt Inc has 127 shs for 0% of their capital. Alps Advsr invested in 0.02% or 60,670 shs. Northern Trust holds 0% or 437,397 shs. Baker Bros Limited Partnership invested 0.05% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Prudential owns 111,093 shs for 0.01% of their capital. The Delaware-based Riverhead Capital Mgmt Ltd Liability Corp has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). California Pub Employees Retirement System accumulated 21,300 shs. State Board Of Administration Of Florida Retirement System holds 19,011 shs. 155,600 were reported by First Manhattan. Evercore Wealth Mgmt Limited Liability Corporation owns 32,742 shs or 0.05% of their US capital. Credit Suisse Ag holds 0% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 51,468 shs. Waddell Reed reported 28,300 shs.

Acceleron Pharma Inc. had 12 selling transactions and 0 buys since January 2, 2018. This’s net activity of $4.08 million. $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Quisel John D on Tuesday, January 2. On Wednesday, January 3 Sherman Matthew L had sold 4,633 shs worth $197,868. The insider POPS RICHARD F sold 37,500 shs worth $1.55 million. On Tuesday, April 3 4,000 shs were sold by MCLAUGHLIN KEVIN F, worth $153,792. $182,363 worth of stock was sold by Kumar Ravindra on Tuesday, January 2.

Acceleron Pharma Inc. (NASDAQ:XLRN) increased significantly to $48.60. On Jun, 29 the move was announced by It has $2.23 billion MC. The company’s valuation will be $66.75M more at $50.06 target.

Acceleron Pharma Inc. (NASDAQ:XLRN)’s earnings report is awaited by WallStreet on August, 2, RTT reports. earnings per share of $-0.64 is 16.88 % up from 2017’s $-0.77 EPS. 10.34 % negative EPS growth is what Wall Street’s predicts after $-0.58 reported EPS last quarter.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

In total 7 analysts cover Acceleron Pharma (NASDAQ:XLRN). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. (NASDAQ:XLRN) has 71% bullish analysts. 9 are the (NASDAQ:XLRN)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 Barclays Capital maintained the shares of XLRN in report with “Overweight” rating. In Friday, June 29 report Credit Suisse maintained the stock with “Outperform” rating. On Monday, January 8 the firm has “Buy” rating by H.C. Wainwright given. In Thursday, March 1 report Citigroup maintained the stock with “Buy” rating. On Friday, June 29 the stock has “Neutral” rating by Goldman Sachs. In Wednesday, February 28 report H.C. Wainwright maintained it with “Buy” rating and $62.0 target. On Monday, February 26 the stock has “Overweight” rating by JP Morgan. On Wednesday, March 28 the firm has “Buy” rating by H.C. Wainwright given. In Tuesday, May 22 report Oppenheimer initiated the stock with “Hold” rating.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news announced briefly go to:,,, or The titles are as follows: “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” announced on June 29, 2018, “Form 8-K ACCELERON PHARMA INC For: Jun 15” on June 20, 2018, “Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society” with a publish date: June 26, 2018, “Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher” and the last “Big News Is Fast Approaching for Celgene” with publication date: June 08, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The company has $2.23 billion market cap. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Last it reported negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.